Travel Distance and Insurance Status: Association With Treatment Access and Survival Among Patients With Hepatocellular Carcinoma
Journal of Surgical Oncology · 2025-09 · 132 (4) · 666-675
DOI: 10.1002/jso.70047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 17.07.2025. Verfasst von Miho Akabane und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Health Services Accessibility, Travel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Travel distance to healthcare facilities can affect hepatocellular carcinoma (HCC) treatment access, but its association with treatment rates, delays, and overall survival (OS) remains unclear. We evaluated the association of travel distance and insurance status with treatment receipt, delays, and OS.
Methods
Patients diagnosed with HCC (2000–2019) were identified from National Cancer Database. Travel distance was categorized as Near (0–10 km), Medium (10–30 km), and Far (> 30 km). Multivariable logistic regression and Cox proportional hazards models were performed.
Results
Among 191,742 patients, 47.9% had Medicare, 29.7% Private insurance, 14.9% Medicaid, and 5.5% were uninsured. Treatment rates increased with distance (Near: 40.9%, Medium: 43.7%, Far: 48.4%; p < 0.001), as did treatment at academic centers (Near: 43.3%, Medium: 52.0%, Far: 67.0%; p < 0.001). Private insurance was more common among individuals traveling farther ( p < 0.001). Medicaid and uninsured patients were less likely to receive surgical/local treatment than Private or Medicare patients ( p < 0.001). Distance (Medium vs. Near: OR 1.155; Far vs. Near: OR 1.440) and insurance (Private vs. Uninsured: OR 2.457; Medicare: OR 2.262; Medicaid: OR1.549) were associated with treatment receipt. Longer distances were associated with higher odds of treatment delays (Medium vs. Near: OR 1.116; Far vs. Near: OR 1.267). Five year OS was lowest in Near (18.0%) and highest in Far (27.6%) distance cohorts. On multivariable analysis, facility type (Community: HR 1.819; Comprehensive: HR 1.409; Integrated: HR 1.151 vs. Academic) and insurance (Private: HR 0.657; Medicare: HR 0.683; Medicaid: HR 0.809 vs. Uninsured) remained associated with OS.
Conclusions
Travel distance and insurance status influenced HCC treatment access. Traveling farther resulted in treatment at academic centers and better OS but increased delays. Private insurance improved access, yet disparities persist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
- Department of Surgery, Stanford University, Stanford, CA, USA.
ORCID-Profile: Timothy M Pawlik
Zitieren
APA
Akabane, M., Altaf, A., Kawashima, J., Imaoka, Y., & Pawlik, T. M. (2025). Travel Distance and Insurance Status: Association With Treatment Access and Survival Among Patients With Hepatocellular Carcinoma. Journal of Surgical Oncology, 132(4), 666-675. https://doi.org/10.1002/jso.70047
Vancouver
Akabane M, Altaf A, Kawashima J, Imaoka Y, Pawlik TM. Travel Distance and Insurance Status: Association With Treatment Access and Survival Among Patients With Hepatocellular Carcinoma. Journal of Surgical Oncology. 2025;132(4):666-675. doi:10.1002/jso.70047
BibTeX
@article{Akabane2025,
author = {Akabane, Miho and Altaf, Abdullah and Kawashima, Jun and Imaoka, Yuki and Pawlik, Timothy M},
title = {Travel Distance and Insurance Status: Association With Treatment Access and Survival Among Patients With Hepatocellular Carcinoma},
journal = {Journal of Surgical Oncology},
year = {2025},
volume = {132},
number = {4},
pages = {666--675},
doi = {10.1002/jso.70047}
}
EUVIMED